T. Rowe Price Investment Management, Inc. Akero Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,102,049 shares of AKRO stock, worth $23.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,102,049Holding current value
$23.6 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$131 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$117 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$112 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$112 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$105 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $996M
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...